Company

Financial Tearsheet

Company Overview

Petros is a Men’s Health pharmaceutical company that aims to develop complementary therapeutics designed for a man’s journey, often, we believe, centered around the ones he loves and lives for. Petros aims to revolutionize the art and science behind the way men approach their health emphasizing the critical elements of medication adherence, tolerability, preservation of organic function and the restoration of vitality.

Each element approached within an integrated and interdependent perspective, targeting tangible enhancements to their health outcomes. Ultimately, Petros seeks to establish new foundations to Men’s Health that center around the whole of a man’s life and function.

Recent Financial News

IR Contacts

CoreIR

IR@PetrosPharma.com

Stock Performance

Stock Fundamentals Value
Today's Open 1.59
Volume 31,298
Day Range 1.59 - 1.75
52 Week Range 1.56 - 5.96
Bid/Ask 1.63 / 1.65
Bid/Ask Size 700 X 1,300
Previous Close 1.59
Market Cap 16.12 million
Shares Outstanding 9.83 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) N/A
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing DateSort Arrow Form Type Description View
Aug 16, 2021 10-Q Quarterly report htmlhtml   xbrlxbrl  
May 14, 2021 10-Q Quarterly report htmlhtml   xbrlxbrl  
Mar 31, 2021 10-K Annual report htmlhtml   xbrlxbrl  

Management Team

Fady Boctor, President, Chief Commercial Officer

Mitch Arnold, VP of Finance, Chief Accounting Officer

Robert Weinstein, Interim Chief Financial Officer

Andy Gesek, President of Timm Medical Technologies (subsidiary of Petros Pharmaceuticals)

Board of Directors

John Shulman, Executive Chairman of the Board

Josh Silverman, Vice-Chairman of the Board

Greg Bradely, Board of Directors

Wayne Walker, Board of Directors

Bruce Bernstein, Board of Directors